These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35154909)

  • 1. Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.
    Sommer A; Berndt S; Lerchen HG; Forveille S; Sauvat A; Mumberg D; Kroemer G; Kepp O
    Oncoimmunology; 2022; 11(1):2037216. PubMed ID: 35154909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
    Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
    Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catabolism of antibody drug conjugates and characterization methods.
    Shadid M; Bowlin S; Bolleddula J
    Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
    Ceci C; Lacal PM; Graziani G
    Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell killing by antibody-drug conjugates.
    Kovtun YV; Goldmacher VS
    Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation.
    Lerchen HG; Stelte-Ludwig B; Berndt S; Sommer A; Dietz L; Rebstock AS; Johannes S; Marx L; Jörißen H; Mahlert C; Greven S
    Chemistry; 2019 Jun; 25(35):8208-8213. PubMed ID: 30869180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
    Hasan MM; Laws M; Jin P; Rahman KM
    Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb.
    Chao DT; Su M; Tanlimco S; Sho M; Choi D; Fox M; Ye S; Hsi ED; Durkin L; Yin J; Zhang Y; Kim H; Starling GC; Culp PA
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):315-25. PubMed ID: 23073510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basics and Innovations in Antibody-Drug Conjugates].
    Manabe S
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):681-685. PubMed ID: 39191680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
    Passaro A; Jänne PA; Peters S
    J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
    Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.